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The purpose of the study was to identify predictors of long-term survival in metastatic breast cancer (MBC). A cohort of 96
patients, who received high-dose chemotherapy with autologous stem cell support (HD-ASCT) as part of their treatment, was
analyzed. Percent long-term survival at 10 years was 24.5% (CI 17.2–34.9%) when metastasis was diagnosed and 14.4% (CI 8.7–
23.9%) when MBC was diagnosed. Survival was impacted signiﬁcantly by body mass index (BMI). Median overall survival from
initial diagnosis or from time of metastasis for patients with BMIs ≤ 30 and >30 (obese) was 7.1 (CI 4.4–8.7) and 3.2 years (2.41–
6.75), respectively, or 3.2 or 2.3 years (all P = 0.02). Also, obesity was the only independent patient-related predictor of time to
metastasisandofsurvival.Whileobesityislinkedwithpooroutcomesinearlierstagesofbreastcancer,thishasnotbeenpreviously
reported for MBC.
1.Introduction
Breast cancer is the second leading cause of cancer deaths
in women today after lung cancer. Metastatic breast cancer
(MBC) is deemed incurable and median survival for patients
with cancer that is estrogen receptor (ER) negative or no
longer hormonally responsive is only 18 to 24 months [1, 2].
A variety of molecularly targeted drugs have been devel-
oped for MBC, but to date only, trastuzumab (Herceptin,
Genentech, CA, USA) has shown an overall survival (OS)
beneﬁt of several months [3–5]. Clearly, more eﬀective
treatment strategies and/or improved patient selection are
urgently needed. In the 1990s, high dose chemotherapy fol-
lowed by autologous stem cell transplantation (HD-ASCT)
was pioneered to improve survival. The initial feasibility
studies in small cohorts of patients with advanced stage dis-
ease showed improved survival when compared to historical
controls [6–9]. Subsequent prospective randomized clini-
cal trials comparing HD-ASCT to standard chemotherapy
resulted in improved PFS, but failed to demonstrate OS ben-
eﬁt [10–14]. The results of the last trial of these series with
386 patients with metastatic breast cancer employing HD-
ASCT were reported most recently and conﬁrmed the results
of earlier studies [15]. All together, the lack of convincing
survival data at the expense of high toxicity resulted in the
demise of HD-ASCT as a treatment modality of MBC.
However, while the vast majority of patients with MBC
will succumb to their disease within a relatively short period
of time, 5–10% of patients live longer than 5 years, and
observational data suggest that 1–3% of patients treated with
conventional chemotherapy and/or hormonal manipulation
may experience long-term survival beyond 10–15 years2 International Journal of Breast Cancer
[16–21]. Quite surprisingly, the most impressive long-term
survival rates in excess of 10% were reported with HD-ASCT
[22–24]. Response to treatment, site of metastases, hormone
receptor status, performance status, and short initial disease-
free interval were important prognostic factors for survival
after HD-ASCT and corresponded to prognostic factors
known from treatment with conventional, less aggressive
therapies [25–27]. However, the observation periods in all
those studies rarely exceeded 5 years.
We have studied long-term survival rates as well as the
distinct disease-and patient-related characteristicsthatwou-
ld be predictive of long-term survival in a cohort of patients
with MBC, who were treated at our institution between 1989
and 1999. Treatments for all patients were not limited to, but
included HD-ASCT.
2. Methods
2.1. Patient Population and Data Extracted. Records of all
patients in the bone marrow transplant registry at UCSD
treated with HD-ASCT for MBC between 1989 and 1999
were retrospectively reviewed. All patients were females.
Patients were followed for a median of 65 months from
diagnosis (range 10.4–255.0 months; quartiles 36.7–109.3
months). No patient was excluded from analysis. Data acqui-
sition and patient conﬁdentiality safeguards were approved
by the Institutional Review Board. Age, race, stage at
diagnosis, histology, estrogen receptor (ER) and menopausal
status, body mass index (BMI) in kg/m2 at the time of
HD-ASCT, time to transplant and death, site of metastasis,
and disease status prior to HD-ASCT were extracted. Since
all transplants were carried out prior to routine assessment
of Her-2/neu receptor status, this information was not
part of our analysis. A BMI > 30 was deﬁned as obesity
(http://www.cdc.gov/). Menopause was deﬁned clinically
by absence of menstruation for more than 12 months
(http://www.cancer.gov/).
2.2. Treatments. High dose chemotherapy prior to stem cell
support was platinum based in combination with thiotepa/
etoposide, ifosfamide/etoposide, cyclophosphamide/BCNU,
cyclophosphamide/mitoxantrone, or cyclophosphamide/thi-
otepa. Dosing was strictly weight-based. Body surface area
was allowed to exceed 2m2. Ten patients received HD-ASCT
in ﬁrst line; all other patients received at least one line of
treatment prior to HD-ASCT (median 1; range 0–4).
Hormonal treatments for ER+ patients were administered
at physicians’ discretion. Autologous stem cell rescue was
performed with harvested bone marrow cells in 6 patients.
The other 89 patients received peripherally mobilized stem
cells, 23 of which received grafts supplemented with har-
vested bone marrow cells. Mobilization was achieved with
granulocyte-orgranulocyte/macrophage-colonystimulating
factor with or without cyclophosphamide.
2.3. Assessment of Disease Status. Extent of metastatic disease
was determined within 12 weeks prior to and within 6–
12 weeks after HD-ASCT by imaging and physical exam.
Thereafter, assessment of disease status was prompted by
Table 1: Patient and disease characteristics.
N
Race
White 81
Hispanic 7
Asian 4
African-American 4
Age at metastasis
<age 40 19
≥age 40 77
Menopausal status at diagnosis
Premenopausal 28
Postmenopausal 68
Unknown 2
BMI at metastasis
<30 73
≥30 23
Stage at diagnosis
Stage I 21
Stage II 43
Stage III 23
Stage IV 8
Unknown 1
Histology
Inﬁltrating ductal 79
Inﬁltrating lobular 10
Unknown 7
Estrogen receptor status
Positive 57
Negative 36
Unknown 3
Site of metastasis
Visceral 38
Bone 28
Lymph nodes 14
Local 16
patient symptoms and carried out at physicians’ discretion.
Patients were grouped according to site of metastasis:in
visceral or bone metastasis, or local or nodal recurrence. If
multiple sites of metastasis were present, assignment to one
metastatic site was prioritized as follows: visceral > bone
> nodal > local. Complete response (CR), partial response
(PR), stable disease (SD), and progressive disease (PD) were
determined according to RECIST criteria.
2.4. Statistical Analysis. Multiple linear regression models
were used to explore the association between a continuous
outcome and predictors of interest. Residual analysis was
performed to check for outliers, normality assumption,
and heteroscedasticity. Transformation was done on the
outcomes if necessary. Brookmeyer and Crowley’s 95% con-
ﬁdence intervals were used for median survival times [28].International Journal of Breast Cancer 3
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Figure 1: Overall survival and progression-free survival for all patients (n = 96) from initial diagnosis (a) and diagnosis of metastasis (b).
Survival was estimated by Kaplan-Meier method.
PFS and OS were estimated using Kaplan-Meier method.
Cox models were used to identify independent predictors
of a time-to-event variable and Schoenfeld tests were used
to test for proportional hazard assumptions. Predictors of
interest with P<0.2 in the univariate analysis were included
in an initial model and a manual backward selection was
made based on the Wald test P values. One subject with an
unknown stage value was excluded from the ﬁnal models.
All analyses used the statistical package R version 2.5.1, 2007.
(http://www.r-project.org/).
3. Results
3.1. Patient and Disease Characteristics. Patient-related char-
acteristicsarelistedinTable 1.Medianageatinitialdiagnosis
was 43 years (quartiles 38–49) and 47 years (quartiles
41–43) at metastasis. Median time from initial diagnosis
to documentation of metastasis was 29 months (quartiles
16.6–63.7), and from metastasis to HD-ASCT 6.6 months
(quartiles 4.5–16.6), respectively. Twelve patients received
HD-ASCT as their ﬁrst line of treatment, whereas84 patients
had at least one prior line of chemotherapy for metastatic
disease (48 patients with 1 line, 24 with 2 lines, 10 patients
with 3 lines, and 2 patients with 4 lines of chemotherapy).
Median BMI at metastasis was 25 (quartiles 21.4–29.6) and
24% of patients were obese (BMI > 30).
3.2. Survival Rates and Inﬂuence of BMI on Survival. For all
patients(n = 96),medianPFSandOSwere3.9years(CI2.9–
5.4) and 5.6 years (CI 4.1–7.4) after initial diagnosis, and 1.6
years (CI 1.3–1.9) and 2.7 years (CI 2.3–3.9) after diagnosis
of metastatic disease, respectively (Figures 1(a) and 1(b)).
Survival rates at 10 years were 24.5% (CI 17.2–34.9%) from
diagnosis and 14.4% (CI 8.7, 23.9%) from when metastatic
disease was diagnosed. As depicted in Figure 2,P F Sa n d
OS diﬀered signiﬁcantly for patients with a BMI ≤ 30 and
>30. At diagnosis, median PFS for patients with BMIs ≤ 30
(n = 73) and >30 (n = 23) was 4.4 (CI 3.6–6.7) and
2.5 years (CI 1.7–4.9), and median OS was 7.1 (CI 4.4–
8.7) and 3.2 years (2.41–6.75), respectively (Figure 2(a) and
2(c); all P values = 0.001; univariate). Once metastasis was
diagnosed, median PFS for patients with BMIs ≤ 30 and >30
was 1.8 (CI 1.44–2.77) and 1.04 years (0.9–1.96) years, and
median OS was 3.20 (CI 2.42–4.30) and 2.30 years (CI 1.56–
4.96), respectively (Figure 2(b) and 2(d); all P values< 0.02;
univariate).
3.3. Independent Predictors of Time from Initial Diagnosis
to Metastasis. Ethnicity, stage at diagnosis, histology, site of
metastasis, remission prior to HD-ASCT, menopausal status,
ages at HD-ASCT and at diagnosis (< age 40 versus ≥ age
40), BMI (≤ 30 versus > 30), and ER status were evaluated
as independent predictors of PFS and OS. In a univariate
analysis, BMI, stage at initial diagnosis, and histology were
predictive of time from initial diagnosis to metastatic disease
(all P values< 0.01). As depicted in Table 2, only the initial
stage at diagnosis and BMI were conﬁrmed as independent
predictors in a multivariate multilinear regression analysis.
Time to metastasis was signiﬁcantly shorter for patients with
aB M I> 30 (Table 2). Median time to metastasis was 1.14
years for patients with a BMI > 30 compared to 1.85 years for
patients with a BMI ≤ 30 (P<0.04 for time to metastasis).
Times to metastasis were similar for stage I or II disease
(approximately 2 years), but time to metastasis shortened
signiﬁcantly compared to stage I or II disease when stage III
was present at diagnosis (0.72 years, P<0.0006).
3.4. Independent Predictors of Survival from Metastasis. Stage
at diagnosis, ER-status, site of metastasis, remission status
prior to HD-ASCT, and BMI were considered for multivari-
ate analysis since univariate P values were< 0.02. Only BMI,
stage at diagnosis and site of metastasis were conﬁrmed to be
independent predictors of survival at the time of metastasis
(Table 3). Patients with a BMI > 30 had a signiﬁcantly higher4 International Journal of Breast Cancer
Table 2: Independent risk factors for time from initial diagnosis to metastasis.
Years from initial diagnosis to metastasis
Median (Q1, Q3) Multiple linear model∗
Coeﬃcients (95% CI) P
n Intercept:0.87 (0.48, 1.26 )
BMI
<30 73 1.85 (0.97, 3.26 ) Ref
≥30 23 1.14 (0.32, 1.97 ) −0.44 (−0.85, −0.02 ) 0.04
Stage at diagnosis
I 21 2.06 (1.37, 3.26 ) Ref
II 43 2.01 (1.41, 3.29 ) 0.02 (−0.44, 0.48) 0.92
III 23 0.72 (0.19, 1.94 ) −0.93 (−1.46, −0.41) 0.0006
IV (=metastasis) 8 N/A N/A N/A
∗ log(years from initial diagnosis to metastasis+0.1) was used as the outcome.
Table 3: Independent risk factors for progression-free survival (PFS) and overall survival (OS) at diagnosis of metastasis.
n
PFS OS
HR (95%CI) HR (95% CI)
HR (95% CI) P HR (95% CI) P
BMI
<30 72 1 1
≥30 23 2.23 (1.28, 3.88) 0.005 1.82 (1.03, 3.23) 0.04
Stage at diagnosis
Stage I 21 1 1
Stage II 43 5.09 (2.55, 10.16) < 0.001 2.87 (1.53, 5.4) 0.001
Stage III 23 3.58 (1.61, 7.94) 0.002 2.61 (1.22, 5.58) 0.01
Stage IV 8 6.88 (2.54, 18.6) < 0.001 3.88 (1.52, 9.9) 0.04
Site of metastasis
Local 16 1 1
Nodal 14 1.37 (0.59, 3.2) 0.47 1.38 (0.6, 3.16) 0.45
Bone 28 1.79 (0.84, 3.82) 0.13 1.60 (0.76, 3.38) 0.22
Visceral 37 4.45 (2.12, 9.37) < 0.001 2.54 (1.25, 5.15) 0.01
hazard of progression and death compared to patients with
aB M I≤ 30 (HR for progression=2.23; P = 0.005; HR for
death=1.82;P = 0.04).Also,oncemetastasiswasdiagnosed,
hazards of progression and death increased signiﬁcantly with
increasing stages present at diagnosis (compared to stage I all
P values< 0.05; Table 3) or with visceral disease.
4. Discussion
In the 1990s, high HD-ASCT was thought to be a beneﬁcial
treatment option in MBC, based on the hypothesis that
signiﬁcant dose escalation would improve the eﬃcacy of
chemotherapy. When several randomized trials demon-
strated that OS was not signiﬁcantly improved [1–15]. HD-
ASCT was abandoned. Since cure could not be achieved
with aggressive treatment, the school of thought changed
and sequential single agent chemotherapy with or without
biologicaltargetedtherapiesand/orhormonalmanipulation
in ER+ patients has become the preferred way of symptom
control [2, 29].
However, a proportion of patients with MBC can achieve
long-term survival which has been reported to exceed 10%
with more aggressive chemotherapy such as HD-ASCT [22–
24]. We were speciﬁcally interested if such high percentages
of survival could be maintained beyond 10 years, at which
point it is possible that at least some of these patients may
be cured of their disease. Second, we studied the patient-
and disease-speciﬁc characteristics predictive of survival. For
both questions we analyzed our institutional cohort of 96
patients with MBC who had received HD-ASCT as part
of their treatment algorithm. Since the last patient was
transplanted in 1999, each patient had a minimum follow-
up of 10 years.
First, we did ﬁnd long-term survival in excess of 10 years.
Survival rates at 10 years were 24.5% from initial diagnosis
and 14.4% from when metastatic disease was diagnosed.International Journal of Breast Cancer 5
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Figure 2: Overall survival (OS) from diagnosis (a) and from time of metastasis (b) and progression-free survival (PFS) from diagnosis (c)
and from time to metastasis (d) in patients with a BMI ≤ 30 (n = 73) or >30 (n = 23). Survival was estimated using Kaplan-Meier method.
Second, and most surprisingly, in univariate and multi-
variate analyses, obesity was the only patient-related factor
associated with signiﬁcantly shorter OS and PFS from initial
diagnosis and from when metastasis was diagnosed. Obesity
also predicted shorter time from diagnosis to metastasis.
Obesity has previously been reported as a risk factor for
survival in patients diagnosed with earlier stages of breast
cancer [30–32] and seems associated with higher stages at
diagnosis [33], but, to the best of our knowledge, this is
the ﬁrst study reporting obesity as a risk factor for survival
in patients with MBC. Other patient-related factors such as
age, ethnicity, and menopausal status were not signiﬁcant.
Weightsandobesitystatuswerenotavailabletousatthetime
of initial diagnosis, but recorded at the time of metastasis
prior to ﬁrst treatment. The median interval between initial
diagnosis and time to metastasis was only approximately 3
y e a r sa n dc a np r o b a b l yb ec o n s i d e r e dat i m ef r a m ew h e r e
major weight changes are not expected to occur for the
majority of patients [34]. We therefore felt comfortable to
use the weight obtained at metastasis as the representative
personal weight for each patient.
Third, among disease-related characteristics, stage at
diagnosiswasanindependentpredictoroftimetometastasis.
Histology and ER-status were not predictive in our cohort.
Her-2/ neu was not part of the analysis since it was not
routinely tested prior to 1999. At the time of metastasis,
in addition to stage at diagnosis, visceral metastasis also
became an independent predictor of a higher hazard for
progression and, suggestively, shortened OS. Higher stages
at diagnosis are known to be associated with shorter time
to recurrence and poorer survival [35, 36], and increased
likelihood of occult metastasis in permissive niches such as
the bone marrow and/or biologically more aggressive forms
of cancer with increased burden of disease were suggested
as plausible explanations for poorer survival at higher stages
[37, 38]. Also, visceral metastasis has been reported before as
apr edict orofpoorsurvi valinMBC[25–27].Theassociation
of poorer outcomes with higher stages at initial diagnosis or6 International Journal of Breast Cancer
visceral metastasis seems uniformly accepted, and our study
supports these previous ﬁndings. The most important and
novel ﬁnding was the negative eﬀect of obesity on survival in
MBC, and its importance as independent predictor of time
to metastasis and progression. To the best of our knowledge,
these results provide ﬁrst strong evidence that elevated BMI
may contribute signiﬁcantly to poor survival in MBC and
these data were ascertained in the setting of HD-ASCT.
While it has been reported that obesity is associated with
higher stages of breast cancer at diagnosis [33], and that
obesity negatively impacts various outcome factors in earlier
stages of breast cancer [30–32], the eﬀects of obesity have
not been directly studied in MBC. Speciﬁcally in respect to
locoregional breast cancer, two prospective studies identiﬁed
obesity as an independent risk factor for overall mortality,
distant and contralateral recurrence, and death from breast
cancer [31, 32]. Similar ﬁndings for all presentations of
breast cancer (some of which had MBC) were reported
in the Prospective Analysis of Case-control studies on
Environmental factors and Health (PACE) study [30].
In general, it is increasingly recognized that obesity
and cancer are linked and that obesity not only confers a
higher risk of cancer incidence but also increases cancer
mortality as demonstrated in three large population-based
cohort studies [39–41]. The reasons are poorly understood,
but tumor growth stimulation by adipokines released from
fatty tissue, inﬂammation [42–44], and especially in the
case of breast cancer increased estrogen levels in obese
postmenopausal females fueling tumor growth [45, 46]
are implicated. Also, adjuvant undertreatment of obese
patients, if chemotherapy is not strictly weight-based [47–
49], is increasingly recognized as important for early relapse.
Against physicians’ beliefs, chemotherapy in the obese is well
tolerated, and, while dose increases proportional to weight
do not confer a higher risk for toxicity [49, 50], under-
dosing in the obese breast cancer patient receiving adjuvant
chemotherapy demonstrated increased risk for recurrence,
shorter DFS or OS [51, 52]. Despite these data, two recent
surveys show that only 25% of breast cancer patients receive
strictly weight-based dosing during adjuvant chemotherapy
andthat19of44cooperativegrouptrialsuseddoselimitsfor
theobese[47,48].Inourstudypopulation,dosesofprevious
adjuvant regimens were unknown, and suboptimal adjuvant
treatment cannot be ruled out as a reason for faster time to
metastasis in the obese. However, agents used for treatment
in the metastatic setting and for HD-ASCT were dosed by
actual body weight, and body surface areas were allowed to
exceed2m2,suchthatunderdosing does not appeartobethe
main reason for poorer outcome parameters. Further study
limitationsareabsenceofHer-2-neuasimportantprognostic
marker, since it was not routinely available in the era of
HD-ASCT, and patient population diversity. Selection bias
may be present since not every patient deemed a candidate
for HD-ASCT may have been referred or proceeded to HD-
ASCT. Factors such as, but not limited to, physicians’ or
patients’ treatment preferences, patients’ performance status
and socioeconomic status may have interfered.
Until now, obesity and its eﬀect on outcomes in MBC
have not been examined in depth, and this is the ﬁrst
report to implicate obesity in poorer outcomes. While
this observation was made in the setting of HD-ASCT,
conclusions about the contribution of HD-ASCT to long-
term survivorship cannot be made, given retrospective
study design, diverse study patient population, and mixed
treatment algorithms. However, our results demonstrate
that ultra-long-term survivorship can be achieved in the
settingofmoreaggressivechemotherapywithHD-ASCTand
that obesity was deleterious in MBC. In contrast to MBC,
correction of unhealthy life-style behavior associated with
obesity is the subject of intense exploration after adjuvant
treatment for breast cancer, where patients are oﬃcially
recognized as “breast cancer survivors.” Results from the
Women’s Healthy Eating and Living (WHEL) study [53]
suggest that obese patients can experience signiﬁcant overall
survival beneﬁt if compliant with a combination of diet and
exercise. We believe that our ﬁndings generate the hypothesis
that obesity may be a potentially correctable patient-related
adverse survival factor in MBC and, similar to approaches
for locoregional stages of breast cancer, can serve as a target
for intervention given the prospect of long-term survival in
certain settings.
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